Optimization of the Efficacy and Safety of Nalbuphine Combined with Esketamine for Post-Cesarean Analgesia: A Randomized, Double-Blind, Parallel-Controlled Clinical Study

Start Date01 Jul 2025

Sponsor / Collaborator-

NCT07034950

/ RecruitingPhase 1/2IIT

Study on the Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation Under Hilar Nerve Blockade

Effective pain management during percutaneous thermal ablation of liver tumors outside the operating room remains a significant challenge. While hepatic hilar nerve block (HHNB) provides partial analgesia, its incomplete efficacy often requires opioid supplementation, potentially increasing perioperative risks. Esketamine, an N-methyl-D-aspartate receptor antagonist, exhibits unique dual analgesic-sedative properties that may address this therapeutic gap, thus obviating the necessity for opioids. This prospective dose-finding study aimed to establish the median effective dose (ED50) and 95% effective dose (ED95) of esketamine for opioid-free analgesia during ultrasound-guided thermal ablation of liver tumors under HHNB. Afterwards, the investigators will conduct an RCT study to evaluate the safety of the dose of esketamine ED95 through the incidence of respiratory depression.

Start Date01 Jul 2025

Sponsor / Collaborator

The First Affiliated Hospital of Xiamen University

NCT07034963

/ RecruitingPhase 1/2IIT

Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care

Cervical dilation-induced somatic responses remain a critical challenge in ambulatory hysteroscopic surgery. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, exhibits unique analgesic and sedative properties that may enhance perioperative somatic response inhibition. However, the effective dose of esketamine under dexmedetomidine-remifentanil based monitored anesthesia care (MAC) during ambulatory hysteroscopic surgery remains to be determined. This prospective dose-finding study aimed to establish the median effective dose (ED50) and 95% effective dose (ED95) of esketamine for cervical response suppression. Afterwards, the investigators will conduct an RCT study to evaluate the safety of the dose of esketamine ED95 through the incidence of respiratory depression.

Start Date01 Jul 2025

Sponsor / Collaborator

The First Affiliated Hospital of Xiamen University

100 Clinical Results associated with Esketamine Hydrochloride

100 Translational Medicine associated with Esketamine Hydrochloride

100 Patents (Medical) associated with Esketamine Hydrochloride

2,489

Literatures (Medical) associated with Esketamine Hydrochloride

31 Dec 2025·ANNALS OF MEDICINE

Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial

Article

Author: Chen, Huihe ; Guan, Xuehai ; Luo, Jiaxin ; Wu, Xiaoshan ; Cao, Huiyu ; Lan, Hongmeng ; Lin, Yuliu ; Zhang, Cuiwen ; Liao, Yeqing ; Huang, Xiaofang

BACKGROUND:

A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression. We compared the incidence of esketamine- and fentanyl-induced respiratory depression in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

METHODS:

This study included 176 women (aged 18-60 years) scheduled for abortion surgery or curettage. Patients were randomized into the fentanyl or esketamine groups. Patients in the fentanyl group received fentanyl (1 µg/kg) combined with propofol intravenously. Patients in the esketamine group received subanaesthetic doses of esketamine (0.15 mg/kg) combined with propofol intravenously. The primary outcome was the incidence of respiratory depression during anaesthesia. Secondary outcomes included respiratory rate, pulse oximetry, blood pressure, heart rate, propofol dose, duration of surgery, duration of anaesthesia, and adverse events.

RESULTS:

The incidence of respiratory depression in the esketamine group was significantly lower than that in the fentanyl group (11% vs. 45%; p < .0001). Propofol administration was lower with esketamine than fentanyl. Respiratory rate, SpO₂ and blood pressure were more stable in the esketamine group than in the fentanyl group. The incidences of hypotension, propofol-induced injection pain and chin lifting in the esketamine group were lower than those in the fentanyl group. The incidence of nightmares was higher in the esketamine than in the fentanyl group.

CONCLUSIONS:

The incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.KEY MESSAGESOpioids combined with propofol is a popular method for non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression.At subanaesthetic doses, esketamine provides an analgesic effect by antagonizing the N-methyl-d-aspartate receptor.In this trial, the incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

31 Dec 2025·ANNALS OF MEDICINE

Opioid-free anaesthesia to reduce postoperative nausea and vomiting after lower extremity wound surgery: a randomised double-blind crossover trial

Article

Author: Liu, Hua-yue ; Ying, Yao-yu ; Qian, Long ; Zhu, Ya-juan ; Ji, Fu-hai ; Liu, Hong ; Peng, Ke

BACKGROUND:

Postoperative nausea and vomiting (PONV) are common complications after surgery. Opioid use is a significant risk factor. We utilised a crossover design to test this hypothesis in the same individuals that opioid-free anaesthesia (OFA) compared with opioid-inclusive anaesthesia reduces PONV.

METHODS:

This randomised double-blind crossover trial included adult patients undergoing two surgical procedures for lower extremity wounds under general anaesthesia. Each patient received both OFA (i.v. lidocaine, esketamine, dexmedetomidine and propofol) and opioid-inclusive anaesthesia (sufentanil and propofol); which came first was determined by randomisation. The primary outcome was the incidence of PONV during the first 48 h postoperatively. Secondary outcomes were the severity of PONV, use of rescue antiemetics, postoperative pain, need for rescue analgesia, adverse events, time to extubation, and length of recovery room stay.

RESULTS:

Sixty-six patients completed this study (mean age 53 years, 36% female). The median washout period was 9 days. Compared with opioid-inclusive anaesthesia, OFA reduced the incidence of PONV 0-48 h postoperatively (5% vs. 23%, odds ratio [OR] = 0.13, 95% CI: 0.03-0.55, p = 0.006), which remained significant in the prespecified adjusted analysis (OR = 0.06, 95% CI: 0.01-0.32, p = 0.001). OFA also led to a reduced severity of PONV, a lower rate of hypotension, and a longer time to extubation. Postoperative pain and other outcomes were similar between the two anaesthetic techniques.

CONCLUSION:

This crossover trial demonstrates that OFA reduced PONV following lower extremity wound surgery, providing compelling evidence for the administration of OFA to enhance perioperative care.

REGISTRATION:

ChiCTR2200061511 (https://www.chictr.org.cn).

31 Dec 2025·ANNALS OF MEDICINE

Effects of esketamine infusion on tourniquet-induced hypertension in patients undergoing below-knee orthopedic surgery: protocol for a randomized controlled trial

Article

Author: Ying, Yao-yu ; Shi, Hai-jing ; Ji, Fu-hai ; Jiang, Kai ; Peng, Ke ; Zhao, Wen-qian ; Zhuang, Min-yuan

INTRODUCTION:

Application of a tourniquet reduces surgical bleeding while causing pain and tourniquet-induced hypertension (TIH). Deeper anesthesia and additional opioids are often insufficient to mitigate TIH but are associated with prolonged recovery and complications. Herein, we describe the protocol for a clinical trial investigating whether intraoperative esketamine infusion would reduce the rate of TIH during below-knee orthopedic surgery.

PATIENTS AND METHODS:

This prospective, randomized, double-blind, controlled trial will include a total of 80 adults scheduled for below-knee orthopedic surgery under general anesthesia. Patients will be randomly assigned in a 1:1 ratio to receive either esketamine infusion at 0.25 mg/kg/h or normal saline infusion after anesthesia induction and during tourniquet inflation. Both groups will receive ultrasound-guided unilateral popliteal sciatic nerve block and adductor canal block with 0.25% ropivacaine. The primary outcome is the occurrence of TIH, defined as an increase in systolic blood pressure >30% of baseline during tourniquet inflation. Secondary outcomes include the incidence of hypotension during surgery; intraoperative hemodynamic changes; intraoperative opioid dose and total amount of esmolol; postoperative nausea and vomiting, dizziness, and mental side effects; postoperative pain at 1, 6, 12, and 48 h after surgery; postoperative analgesic consumption within 48 h after surgery; and length of postoperative hospital stay. Additionally, we will assess patients' quality of recovery at 24 h after surgery.

DISCUSSION:

This trial will determine the effects of esketamine infusion on TIH in patients who undergo below-knee orthopedic surgery under general anesthesia. Our results will offer a new insight into optimizing anesthetic care for surgical patients receiving tourniquet.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR2400081237).

359

News (Medical) associated with Esketamine Hydrochloride

23 Jun 2025

·www.biopharmadive.com

Compass’ big psychedelic study doesn’t impress investors

One of the most closely watched clinical trials in the burgeoning field of psychedelics research has delivered results that, while positive, appear to have unnerved some investors.Sponsored by U.K.-based biotechnology company Compass Pathways, the trial enrolled 258 people with treatment-resistant depression. Participants were given either a placebo or the companys proprietary version of psilocybin a psychedelic compound found in many mushroom species and evaluated for an initial period of six weeks.According to Compass, a single dose of its drug significantly reduced scores on a 60-point scale healthcare providers use to gauge depressive symptoms.Specifically, the drug arm showed a 3.6-point larger decline on that scale compared to its placebo counterpart. Compass also said an independent group of experts reported that the drugs safety looks consistent, with no unexpected findings in this study or another ongoing, late-stage trial. That group has not observed any clinically meaningful imbalance in suicidality between the treatment arms in either experiment.In a statement, Guy Goodwin, Compass chief medical officer, said the company is very encouraged by the new data, which mark an important milestone for patients whose depression hasnt been adequately treated through multiple approved options. This achievement provides hope that they can finally receive appropriate care and live the life they deserve.Investors, though, didnt seem as enthused. Compass shares were down by nearly 50% Monday morning, to trade below $3 apiece.Leonid Timashev, an analyst at RBC Capital Markets, noted how in earlier testing, patients on Compass drug experienced a roughly 6-point reduction on that depression severity scale. The RBC team also spoke to important doctors in the depression field, who, while open to using any effective agents, said a 4-point-or-more decline would be the bar to aim for.Shareholders therefore wanted to see a separation at least somewhere in the middle, around 5 points, according to Timashev. They were likely disappointed, then, by the readout as well as Compass release, which contained no details on response rates, remission rates or the drugs lasting power. Those are important details investors may be looking for to gauge the drug's competitive profile, the analyst wrote in a note to clients.While some may be underwhelmed, Timashevs team still views the results as clinically meaningful and in a range that could make Compass drug competitive with Johnson & Johnsons Spravato. That latter medicine, a form of ketamine taken as a nasal spray, won U.S. approval for treatment-resistant depression in 2019. Its since become one of J&Js faster-growing products, fetching nearly $1.1 billion in sales last year.Timashev argued that, at a single dose, Compass drug could hold significant convenience advantages. It might also look better than Spravato at certain time points in their respective studies though cross-trial comparisons are tricky.Evercore ISI analyst Gavin Clark-Gartner took a much less bullish stance and downgraded his stock rating on Compass. With clinical and commercial question marks, the second [Phase 3 study] will remain a show me story for investors in an increasingly competitive landscape, he wrote.To that end, a small, Ireland-based developer recently reported results from a study testing an inhaled version of mebufotenin, a molecular cousin to psilocybin. The 81-person trial found GH Researchs drug to be a fast and effective therapy for treatment-resistant depression, delivering an almost 16-point drop on that scale compared to a placebo.Paul Matteis, an analyst at Stifel who covers both Compass and GH Research, highlighted in his own note the very significant differences between the two companies trials. The main measure in the latters, for example, was taken at the eight-day mark. That study also employed a titration regimen Matteis team believes played a part in attenuating any placebo response.Placebo responses are a major obstacle in psychiatric and psychedelic experiments, so anything that mitigates them could potentially benefit the results.Compass expects to share 26-week results from its other ongoing late-stage trial in the back half of next year. '

Clinical ResultPhase 3Drug Approval

10 Jun 2025

·www.globenewswire.com

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program

NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellenceMALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two significant updates underscoring its ongoing commitment to clinical excellence and innovation in mental health care. This week, NeuroStar will attend the 13th Annual Clinical TMS Society (CTMSS) Meeting, taking place June 11–14 in San Diego, CA as a Silver Sponsor. NeuroStar will present two poster presentations derived from the TrakStar® data set, the largest real-world outcomes database in TMS. Data highlights include a retrospective analysis of Greenbrook’s multi-site study, providing a direct comparison of clinical outcomes between NeuroStar’s proprietary Figure-8 coil and Brainsway’s H-coil in the treatment of depression, offering new insight into device-specific performance. As part of the meeting, the Company will participate in the PULSES Course, a foundational training session for new and experienced TMS providers. Additionally, NeuroStar will exhibit at booth #303. “The data and research initiatives reflect the scientific excellence NeuroStar is known for and are a continuation of our reputation as the leader in contributing to the scientific literature in the psychiatric community,” said Cory Anderson, Chief Technology Officer of Neuronetics. “We will continue to lead the field and put patient outcomes first by investing in valuable research to optimize TMS efficacy and expand its use into new populations and protocols.” The following data will be presented at the CTMSS Meeting: Age is Just a Number: Real-world effectiveness of TMS in late-life depression Presenter: Dr. Eleanor Cole, Senior Director of Clinical Innovation, Neuronetics Inc.Overview: Dr. Cole will present the largest-to-date analysis of elderly adults (age 70 and older) with Major Depressive Disorder (MDD) treated with TMS.Presentation Date: June 13th at 4:00 PM PDT Clinical Outcomes in Patients Treated with NeuroStar and Brainsway TMS Therapy Devices Presenter: Cory Anderson, Chief Technology Officer, Neuronetics Inc.Overview: Mr. Anderson will present data from a retrospective analysis of data from 200 Greenbrook centers evaluating the real-world efficacy of TMS therapy delivered using NeuroStar or Brainsway devices.Presentation Date: June 13th at 4:00 PM PDT Greenbrook Mental Wellness Centers, a wholly owned subsidiary of Neuronetics, has initiated a program to evaluate the feasibility of using personalized qEEG-informed protocols to deliver TMS therapy using the NeuroStar TMS System. To date, the program has demonstrated operational feasibility and the ability to successfully deliver the protocols using a commercially available NeuroStar TMS System. The Company looks forward to sharing their findings in the near future. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Neuronetics Contact:Investors:Mike Vallie or Mark KlausnerICR Healthcare443-213-0499ir@neuronetics.com Media:EvolveMKD646.517.4220NeuroStar@evolvemkd.com 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

02 Jun 2025

·www.einpresswire.com

Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000 ® Index and the small-cap Russell 2000 ® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. The broad-market Russell 3000 ® Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000® Index is a subset of the broader Russell 3000® Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025 this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "This inclusion in the Russell 3000® and Russell 2000® Indexes represents an important validation of our strategic vision and operational execution," said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. "As we continue expanding access to innovative mental health treatments through our integrated approach—combining our leading NeuroStar technology with our growing Greenbrook clinic network—this milestone enhances our visibility among institutional investors and reflects the significant progress we've made in transforming how mental healthcare is delivered. With our path to positive cash flow this year and our proven operating model driving strong growth, we're well-positioned to continue delivering value for both patients and shareholders." About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. “Safe harbor” statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our ability to successfully complete the announced restructuring plans; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our revenue has been concentrated among a small number of customers; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to achieve cash flow breakeven in the third quarter of 2025. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations. Investor Contact: Mike Vallie or Mark Klausner ICR Healthcare 443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD 646-517-4220 NeuroStar@evolvemkd.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Esketamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10627	Esketamine Hydrochloride	N01AX14 N06AX27	DB11823

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	China	Janssen-Cilag International NV	17 Apr 2023
Major depressive disorder, moderate (MDD)	Australia	Janssen-Cilag Pty Ltd.	09 Mar 2021
Depressive Disorder, Major	European Union	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Iceland	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Liechtenstein	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Norway	Janssen-Cilag International NV	18 Dec 2019
Anesthesia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	18 Nov 2019
Depressive Disorder, Treatment-Resistant	United States	Janssen Pharmaceuticals, Inc.	05 Mar 2019
Pain	Germany	Pfizer Inc.	01 Aug 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Suicidal Ideation	Phase 3	United States	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Bulgaria	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Estonia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Germany	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Hungary	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Malaysia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Slovakia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	South Africa	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Spain	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Taiwan Province	Janssen Research & Development LLC	09 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02782104 (SUSTAIN-3, Pubmed \| Int J Neuropsychopharmacol)	Phase 3	Depressive Disorder, Treatment-Resistant	1,148	Esketamine nasal spray + oral antidepressant	aihjnkmquc(vkvywwwgbo) = n = 3 pwmdtppvdn (rhcnlpehao ) View more	Positive	06 Jun 2025
Pubmed \| JAMA Psychiatry Manual	Not Applicable	Depressive Disorder, Treatment-Resistant	-	Esketamine + SNRI	esellocawi(irhdgxkxfd) = earyxgxwme uqehjtcdaq (opsvmwrfms ) View more	Positive	02 Apr 2025
				Esketamine + SSRI	esellocawi(irhdgxkxfd) = mttwgedlfs uqehjtcdaq (opsvmwrfms ) View more
NCT03185819 (Pubmed \| J Am Acad Child Adolesc Psychiatry)	Phase 2	Depressive Disorder, Major	147	Esketamine 28 mg	cddbpjogfz(amddtxnlbl) = incidence ≥20% ktvgzasmhz (bdvdpuuonb ) View more	Positive	01 Mar 2025
				Esketamine 56 mg
NCT05464979 (Pubmed \| Sci Rep)	Phase 4	-	80	Esketamine	lawdfxguja(hsgtvpglug) = rmgtrylaim sdvhtnzvfh (rtljvqecgn, 4.0 - 16.3)	Positive	19 Feb 2025
				Midazolam/sufentanil admixture	lawdfxguja(hsgtvpglug) = pcxqjsdqhe sdvhtnzvfh (rtljvqecgn, 8.0 - 26.0)
ChiCTR2400087873 (Pubmed \| BMC Anesthesiol)	Not Applicable	Sedation \| Anxiety Disorders	90	Intranasal Dexmedetomidine	jdusnvlpsg(euylahoqtz) = bradycardia, hypotension, hypoxia, emergence delirium etc. kvbzxnsdmt (wffppszemr )	Positive	11 Feb 2025
				Intranasal Dexmedetomidine-Esketamine
ChiCTR2300069632 (Pubmed) Manual	Not Applicable	Pain	135	esketamine	wdgcpqjteh(crgogaimht): P-Value = P<0.05 View more	Positive	20 Jan 2025
				sufentanil
NCT03097133 \| NCT03039192 (FDA_CDER) Manual	Phase 3	Depressive Disorder, Major	-	SPRAVATO 84 mg +SOC (NCT03039192)	ngefszdlxg(mtufbliqfi) = hbejaoitnh ngtsvhkixu (obwwpqahfb, 1.04)	Positive	17 Jan 2025
				Placebo nasal spray + SOC (NCT03039192)	ngefszdlxg(mtufbliqfi) = ntdfgiixek ngtsvhkixu (obwwpqahfb, 1.02)
NCT04599855 (FDA_CDER) Manual	Phase 4	Depressive Disorder, Treatment-Resistant	-	SPRAVATO (56 mg)	rwgqleidtr(zfqcaymwxt) = vdyhscqhyz vloxyfjavg (rfbihudujg, 1.2)	Positive	17 Jan 2025
				SPRAVATO (84 mg)	rwgqleidtr(zfqcaymwxt) = akvkvjqhsi vloxyfjavg (rfbihudujg, 1.2)
NCT06398834 (Pubmed \| Int J Clin Pharm)	Phase 4	Pain, Postoperative	181	Esketamine + Butorphanol	cwardpzdhe(vskljmleic) = wpimfcnlck mpnrmzfpjn (cmfwdxbbmv )	Positive	03 Jan 2025
				Butorphanol	cwardpzdhe(vskljmleic) = eleqifqonx mpnrmzfpjn (cmfwdxbbmv )
NCT03373253 \| NCT02497287 (ICEBERG, Pubmed \| Front Psychiatry)	Phase 3	Functional disorder	696	Esketamine nasal spray + SSRI/SNRI	vzoxbnwpqo(lhzzkmmijn) = tiobrdplfz uwtfxajijb (szwbxabunh, 21.8 - 29.4)	Positive	07 Oct 2024
				esketamine nasal spray (Real-world treatment (RWT))	vzoxbnwpqo(lhzzkmmijn) = ljjsupnjrg uwtfxajijb (szwbxabunh, 6.9 - 16.1)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Esketamine Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation